News | March 06, 2026
Lonza to set up Global Capability Centre in Hyderabad
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Subscribe To Our Newsletter & Stay Updated
